https://www.selleckchem.com/products/bi-2493.html
Further prospective studies are warranted to optimize irinotecan-based chemotherapy in these patients. mCRC patients homozygous for the UGT1A1*28 allele can tolerate irinotecan at an initial dose of 120 mg/m2 with favorable oncological outcomes and toxicity profiles. Further prospective studies are warranted to optimize irinotecan-based chemotherapy in these patients. Impairments in speech and social cognition have been reported in people with multiple sclerosis (pwMS), although their relationships with neuropsychological outcomes and t
Like
Comment
Share
